Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
China National Pharmaceutical Group Modern: Holding Subsidiary Obtains Marketing Authorization for Eperisone Hydrochloride Tablets and Related Rights
People’s Financial News, March 24 — China National Pharmaceutical Group Modern (600420) announced on March 24 that recently, its controlling subsidiary China National Pharmaceutical Group Zhijun (Shenzhen) Pharmaceutical Co., Ltd. (referred to as “China National Pharmaceutical Zhijun”) signed a “Drug Marketing Authorization Transfer Agreement” with Shanghai Boyue Biotechnology Co., Ltd. (referred to as “Shanghai Boyue”). Shanghai Boyue will transfer the marketing authorization and related rights for its developed product, Hydroxyzine Hydrochloride Tablets (50mg), to China National Pharmaceutical Zhijun, with a total transfer fee of 10.5 million yuan. Hydroxyzine Hydrochloride Tablets are central muscle relaxants, with clinical indications including two main areas: one is to improve muscle tension in conditions such as cervical and shoulder-arm syndrome, periarthritis, and back pain; the other is to treat spastic paralysis caused by diseases.